The Role of Surveillance Chest X-Rays in the Follow-Up of High-Risk Melanoma Patients
First Online: 22 November 2008 Received: 03 July 2008 Revised: 18 September 2008 Accepted: 22 September 2008 DOI:
10.1245/s10434-008-0207-5 Cite this article as: Morton, R.L., Craig, J.C. & Thompson, J.F. Ann Surg Oncol (2009) 16: 571. doi:10.1245/s10434-008-0207-5 Abstract
We sought to evaluate the accuracy of detecting asymptomatic pulmonary metastases by surveillance chest X-rays (CXRs) in melanoma patients with a positive sentinel node biopsy. Sentinel node–positive patients treated at the Sydney Melanoma Unit between 1994 and 2003 were prospectively enrolled onto a monitoring schedule of 6 monthly CXRs for 5 years, then annual CXRs for another 5 years. The reference standard for pulmonary metastasis was a positive histopathology diagnosis from a lung biopsy. A total of 108 patients were followed for a median of 52.5 months. A total of 21% (23 of 108) developed pulmonary metastases, which were detected in 48% (11 of 23) by surveillance CXR (sensitivity, 48%; 95% confidence interval [95% CI], .27–.68), leading to resection in 13% (3 of 23). CXRs were abnormal in 19 additional patients but not due to recurrence (specificity, 78%; 95% CI, .77–.79). Additional metastatic disease was apparent in 18% of CXR-detected versus 76% of non-CXR-detected patients (
p < .05), but median time to diagnosis of pulmonary metastases was 24 months (95% CI, 12–41) versus 16 months (95% CI, 10–30, p = .30 log rank) and median survival of 42 months (95% CI, 24–84) versus 36 months (95% CI, 18–46, p = .53 log rank) were not significantly different. The 6 to 12 monthly surveillance CXRs detected only half of pulmonary metastases, infrequently identified patients for potentially curative surgery, and did not lead to earlier detection of pulmonary metastases. Further, they may cause unnecessary patient anxiety, given the high rate of false-positive findings.
The results were presented at the 34th Clinical Oncological Society of Australia (COSA) annual scientific meeting in November 2007.
Gershenwald JE, Thompson W, Mansfield PF, et al. Multiinstitutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients.
J Clin Oncol
Clary BM, Brady MS, Lewis JJ, et al. Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence.
Ann Surg Oncol. 2001;233:250–8.
Chao C, Wong SL, Ross MI, et al. Patterns of early recurrence after sentinel lymph node biopsy for melanoma.
Am J Surg
Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma.
N Engl J Med
Gorenstein LA, Putnam JB, Natarajan G, et al. Improved survival after resection of pulmonary metastases from malignant melanoma.
Ann Thorac Surg
Essner R. Surgical treatment of melanoma.
Surg Clin North Am
Mackie RM, Casinelli N, Ross MI, et al. Clinical management of melanoma. WHO melanoma programme. Milan: Melanoma publications; 1996.
Roberts DL, Anstey AV, Barlow RJ, et al. UK guidelines for the management of cutaneous melanoma.
Br J Dermatol
van Everdingen JJ, van der Rhee HJ, Koning CC, et al. Guidelines to melanoma, 3rd revision.
Ned Tijdschr Geneeskd
Australian Cancer Network. Clinical Practice Guidelines: the management of cutaneous melanoma. NHMRC. Canberra: Commonwealth Department of Health; 1999.
Damian DL, Fulham MJ, Thompson E, et al. Positron emission tomography in the detection and management of metastatic melanoma.
Bland M. An Introduction to Medical Statistics. 3rd ed. Oxford: Oxford University Press; 2000.
Hofmann U, Szedlak M, Rittgen W, et al. Primary staging and follow-up in melanoma patients—monocenter evaluation of methods, costs and patient survival.
Br J Cancer
Tsao H, Feldman M, Fullerton JE, et al. Early detection of asymptomatic pulmonary melanoma metastases by routine chest radiographs is not associated with improved survival.
Weiss M, Loprinzi CL, Creagan ET, et al. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas.
Grimes DA, Schultz KF. Uses and abuses of screening tests.
Sackett DL, Haynes RB, Guyatt GH, et al. Clinical Epidemiology—A Basic Science for Clinical Medicine. 2nd ed. Boston: Little, Brown; 1991.
Dalrymple-Hay MJ, Rome PD, Kennedy C, et al. Pulmonary metastatic melanoma—the survival benefit associated with positron emission tomography scanning.
Eur J Cardiothorac Surg
Tafra L, Dale PS, Wanek LA, et al. Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax.
J Thorac Cardiovasc Surg
Coit DG. Role of surgery for metastatic malignant melanoma: a review.
Semin Surg Oncol
Gareen IF. Noncompliance in cancer screening trials.
Kittler H, Weitzdorfer R, Pehamberger H, et al. Compliance with follow-up and prognosis among patients with thin melanomas.
Eur J Cancer
Nieweg OE, Kroon BR. The conundrum of follow-up. Should it be abandoned?
Surg Oncol Clin N Am
Kelly J, Henderson M, Thursfield V, et al. The management of primary cutaneous melanoma in Victoria.
Med J Aust
Fields MM, Chevlen E. Screening for disease: making evidence-based choices.
Clin J Oncol Nurs
McGovern PM, Gross CR, Krueger RA, et al. False-positive cancer screens and health-related quality of life.
Hewitson P, Glasziou P, Irwig L, et al. Screening for colorectal cancer using the faecal occult blood test, Hemoccult (review).
Cochrane Database Syst Rev. 2007;(1):CD001216.
Baughan CA, Hall VL, Leppard BJ, et al. Follow-up in stage I cutaneous malignant melanoma: an audit.
McCaffery K, Michie S. Monitoring as a learning and motivational tool. In: Glasziou PP, Irwig L, Aronson JK, editors. Evidence-based Medical Monitoring: From Principles to Practice. Oxford: Blackwell; 2008. p 123–39.
© Society of Surgical Oncology 2008